Medicare Part B: Lenmeldy
Customize your policy alerts
Sign up for all MVP Health Care policy alerts
Know when MVP Health Care releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization and coverage of Lenmeldy (atidarsagene autotemcel), an autologous hematopoietic stem cell-based gene therapy, for eligible Medicare Advantage members with specified forms of metachromatic leukodystrophy. It applies to providers requesting administration through the medical benefit.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.